Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells

SHAO-JUN LI*, SHI-JIE SUN, JIE GAO and FU-BO SUN

Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China

Received July 2, 2015; Accepted August 26, 2016

DOI: 10.3892/ol.2016.5367

Abstract. Wogonin is considered to be an inhibitor of myeloid cell leukemia 1 and B-cell lymphoma 2, and a potential antitumor drug due to its ability to induce apoptosis in certain cancer cells; however, few previous studies have reported on wogonin-induced autophagy. The aim of the present study was to investigate the influence of wogonin on autophagy in human pancreatic cancer cells (HPCCs), elucidate its mechanism, and identify strategies to increase its effectiveness as an anti-cancer treatment. HPCCs were treated with wogonin and autophagy was detected in the cells. The mechanism of wogonin-related autophagy was investigated, and the antioxidant N-acetyl-L-cysteine (NAC) was used to assess the role of reactive oxygen species (ROS) in wogonin-related autophagy. The results demonstrated that wogonin may induce autophagy by activating the Beclin-1/phosphatidylinositol-3-kinase and ROS pathways in HPCCs, and may enhance ROS generation, followed by the activation of the AKT/ULK1/4E-BP1/CYLD pathway and inhibition of the mammalian target of rapamycin signaling pathway. The incubation of HPCCs with wogonin and the antioxidant NAC, revealed that the effects of wogonin-enhanced ROS generation on autophagy-related molecules were inhibited, contributing to the inhibition of autophagy and increasing the cell death ratio through apoptosis activation in HPCCs. These studies suggest that autophagy activation, via the ROS pathway, by the antitumor drug wogonin in HPCCs may partially reduce the antitumor effects of the drug, and that the antioxidant NAC may enhance the antitumor effectiveness of wogonin via the inhibition of ROS-enhanced autophagy and the subsequent promotion of apoptosis. Therefore, the present research suggests that wogonin combined with NAC may be a novel combination therapy for clinical pancreatic cancer therapy trials.

Introduction

Pancreatic cancer has a mortality rate of >95%, which has not improved for 3 decades (1). The current treatment of pancreatic carcinoma consists of a combination of chemotherapy (including gemcitabine), radiotherapy and surgery, although the treatment may vary (2). The majority of patients with pancreatic cancer are diagnosed at a late and inoperable stage and the 5-year survival rate is poor (3). In investigating novel therapeutic and preventative strategies, a number of studies have focused on developing novel chemotherapeutic agents. For example, Lewis et al (4) have demonstrated that the sphingosine kinase-2 inhibitor ABC294640 acts as a chemotherapeutic agent for the treatment of pancreatic cancer through suppression of c-Myc and RRMM expression. In addition, Mandhare et al (5) reviewed the effect of Azaepothilone B on chemotherapeutic medication for pancreatic cancer. Pourmorteza et al (6) demonstrated that evofosfamide targets tumor hypoxia, and may be a potential agent against pancreatic cancer. Although numerous novel chemotherapeutic agents have been identified, their antitumor mechanisms, and how these may be manipulated to promote antitumor efficacy, are not clear at present.

Wogonin (5,7-dihydroxy-8-methoxyflavone) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1) and B-cell lymphoma 2 (Bcl-2), which are anti-apoptotic proteins that are expressed in various tumors, including pancreatic cancer (7,8). Previous studies (9,10) have demonstrated the antitumor potential of wogonin, particularly its ability to induce apoptosis and its high maximum-tolerated dose. Wogonin has also been observed to be a potential anti-pancreatic cancer drug through its ability to inhibit the Mcl-1 and nuclear factor-xB (NF-xB) pathways (11,12).

Autophagy has become a novel target for the treatment of certain types of cancer, and may prevent cell death (13). Few studies have previously reported wogonin-induced autophagy (14,15). In present study, wogonin was added into
the medium of HPCCs, and the influence of wogonin on autophagy and its mechanism were investigated. Furthermore, the antioxidant N-acetyl-L-cysteine (NAC) was used as a chemosensitizer of wogonin to detect whether it can enhance cancer cell death, and its mechanism was investigated.

Materials and methods

Cell culture. Panc-1 and Colo-357 HPCCs were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in an atmosphere containing 5% CO₂. HPCCs were treated with 40 µM wogonin, 40 µM wogonin combined with 40 µM chloroquine (CQ), or 50 µM rapamycin for 24 h; in addition, HPCCs were pretreated with sterile water or 10 mM NAC for 2 h and then treated with 0.1% DMSO or 40 µM wogonin for 24 h. All cell culture reagents were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Western blotting. The cells (5x10⁵) were lysed for 30 min in radioimmunoprecipitation assay lysis buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS; Beyotime Institute of Biotechnology, Haimen, China] on ice then centrifuged at 12,000 x g for 12 min at 4°C. A bicinchoninic acid assay (Beyotime Institute of Biotechnology) was used to determine the protein concentration. The proteins were separated by 8-15% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and blotted onto a polyvinylidene difluoride membrane (PVDF) following blocking with 5% nonfat dry milk in phosphate buffered saline (PBS) with 0.05% Tween 20 (PBST). The membranes were incubated with the primary antibodies (dilution, 1:1,000) for 2 h at 37°C, then the PVDF membranes were washed three times for 10 min in PBST. Secondary antibodies (dilution, 1:10,000) were incubated for 1 h at 37°C and the PVDF membranes were then washed three times for 10 min in PBST. The antibodies used included rabbit polyclonal IgG primary antibodies against LC3α (#sc-134226), Beclin-1 (#sc-11427), phosphatidylino-sitol 3-kinase (PI3K; #sc-134766), total mammalian target of rapamycin (mTOR; #sc-8319), phospho-mTOR (#sc-101738), Unc-51-like autophagy-activating kinase 1 (ULK1; #sc-33182) and cylindromatosis (CYLD; #sc-28211), mouse monoclonal IgG₁ primary antibodies against protein kinase B (AKT; #sc-5298), eukaryotic initiation factor 4E-binding protein 1 (4E-BP1; #sc-9977) and GAPDH (#sc-365062), and anti-mouse IgG (#sc-2380) and anti-rabbit IgG (#sc-2385) secondary antibodies. All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Subsequently, the PVDF membranes were exposed to BeyoECL Star (#PO018A; Beyotime Institute of Biotechnology) and ECL-sensitive films, and developed by OPTIMAX X-Ray film processor (Optimax 2010; Protec GmbH & Co. KG, Oberstenfeld, Germany).

Acridine orange (AO) staining. The degradation of autophago-somes is mediated by lysosomes; autolysis lowers the pH value and allows AO dye to penetrate into the acidic organelles and exhibit a red fluorescence; therefore, the intensity of red fluorescence following AO staining can be used to indicate the levels of autolysosomes (16). Cells were treated with dimethyl sulfoxide (DMSO) or 40 µM wogonin for 24 h in DMEM supplemented with 10% FBS at 37°C in an atmosphere containing 5% CO₂, then washed three times with PBS, fixed with 4% paraformaldehyde for 15 min, stained with 1 mg/l AO dye solution for 10 min at 37°C and then imaged under a fluorescence microscope (Nikon TE2000; Nikon Corporation, Tokyo, Japan).

Green fluorescent protein (GFP)-conjugated microtubule-associated protein 1A/B-light chain 3 (LC3) analysis. When autophagy is induced, cytosolic LC3 is cleaved by hydrolysis to a shorter peptide (LC3 II) that is located on the membrane of the autophagosome; therefore, the expression levels of LC3 II may be used to estimate the level of autophagy. In order to estimate the location and processing of LC3-II, assessment of LC3-GFP puncta is an effective method (16). Panc-1 and Colo-357 cells were incubated in 6-well plates with DMEM supplemented with 10% FBS at 37°C in an atmosphere containing 5% CO₂. When they had reached 80% confluence, the cells were incubated with Opti-MEM medium (Thermo Fisher Scientific, Inc.) and transfected with a GFP-LC3 vector (GeneChem Co., Ltd., Shanghai, China) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) for 24 h. Subsequently, the cells were treated with DMSO or 40 µM wogonin for 24 h, then fixed with 4% paraformaldehyde for 15 min, and washed three times with PBS. The cells were imaged under a fluorescence microscope (Nikon TE2000) and LC3-GFP puncta-positive cells were counted (≥5 puncta was considered positive).

Co-immunoprecipitation experiments. Panc-1 cells (5x10⁵) were plated onto 15-cm dishes and attached overnight. The cells were treated with DMSO or 40 µM wogonin for 12 h at 37°C then lysed for 30 min in hypotonic lysis buffer (Beyotime Institute of Biotechnology) on ice and centrifuged (1,000 x g, 4°C, 15 min) as a whole-cell lysate. Whole-cell lysates were precleared with protein A-agarose (50% in PBS), and then incubated with antibodies against Beclin-1 or PI3K (#sc-11427 and #sc-134766; Santa Cruz Biotechnology, Inc.; dilution, 1:300) for 1 h at 4°C. The immunoprecipitates were captured on a protein-A agarose gel and then detected by immunoblotting; whole-cell lysates and immunoprecipitates were separated by 12% SDS-PAGE and transferred to PVDF membranes for detection, as described above (17).

Cell viability assay. Cell Counting kit-8 (CCK8) was used to assess cell viability. Cells (1x10⁵) were seeded into a 96-well plate and incubated overnight in the previously described conditions. The cells were pretreated with sterile water or 10 mM NAC for 2 h and then with 0.1% DMSO or 40 µM wogonin for 24 h. Following this, the medium was removed and the cells were washed three times with PBS. DMEM (90 µl) and CCK8 (10 µl) were subsequently added to each well and incubated for 1.5 h at 37°C; a microplate reader was used to measure the optical density (OD) at 450 nm.

ROS detection. The levels of intracellular ROS generation were detected through measuring the conversion of cell-permeable ROS.
2,7-dichlorofluorescein diacetate (DCFH-DA; Beyotime Institute of Biotechnology) to fluorescent dichlorofluorescein (DCF). Cells (1x10^4) were seeded into 96-well plates and incubated overnight in the standard conditions. The cells were pretreated with sterile water or 10 mM NAC for 2 h and then treated with 0.1% DMSO or 40 µM wogonin for 24 h. The medium was removed and the cells were washed three times with PBS prior to incubation with DCFH-DA at 37˚C for 20 min. A fluorescence microplate reader, with 488 nm excitation wavelength and 525 nm emission wavelength, was used to determine the levels of ROS in the cells.

Detection of glutathione (GSH) and superoxide anions (O2⁻). The intracellular levels of GSH were measured by GSH Assay kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. The OD value of GSH was detected with a fluorescence microplate reader (Tecan, Männedorf, Switzerland) at 420 nm. In addition, the intracellular levels of O2⁻ were detected by Superoxide Assay kit (Beyotime Institute of Biotechnology), and the fluorescence value of O2⁻ was measured at a wavelength of 550 nm.

Trypan blue assay. Following pretreatment with sterile water or 10 mM NAC for 2 h and treatment with 0.1% DMSO or 40 µM wogonin for 24 h, the cells were suspended in 0.25% Trypsin-EDTA (Thermo Fisher Scientific, Inc.), and 0.4% (w/v) trypan blue solution was added to each 2-µl suspension; the ratio of the cell suspension to the trypan blue solution was 9:1. The cells were counted under a light microscope. As the dead cells fail to exclude the dye, the cell death rate was calculated using the following equation: Total cell death rate = (no. dyed cells / total no. cells) x 100%.

Transmission electron microscopy (TEM). TEM is the gold standard for the assessment of autophagosomes (16). Samples were prepared using a previously described method (18). Briefly, the treated cells were washed three times with PBS times, suspended in 0.25% Trypsin-EDTA, rinsed three times in the distilled water and dehydrated in the different concentrations of ethanol (50, 70, 80, 90, 95 and 100%; 8 min each). Subsequently, the cells were placed into propylene oxide for 10 min, and then into Embed 812 Resin medium and propylene oxide mixture (1:1) overnight at room temperature. Samples were then cured in BEEM capsules overnight at 60°C and the sections were cut at 50 nm by use of an ultramicrotome (EM UC7/FC7; Leica Biosystems, Nussloch, Germany). The cut sections were stained with lead citrate and 2% (w/v) uranyl acetate for TEM detection. TEM was
performed on a JEOL 1230 TEM (JEOL, Tokyo, Japan) at an accelerating voltage of 80 kV. Images were acquired with an AMT Advantage Plus 2K x 2K digital camera connected to the TEM (18).

Small interfering RNA (siRNA) transfection experiment. Control siRNA and siRNA specifically targeted to Beclin-1 (GAGAUCUUAGAGCACAUGATT) were purchased from RiboBio Co., Ltd. (Guangzhou, China). Cells were plated in 6-well plates and grown to ~80% confluence before transient transfections with siRNAs (100 pmol per well) were performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific), according to the manufacturer's instructions. After a 36-h transfection, 0.1% DMSO or 40 µM wogonin were added for an additional 24 h prior to collection of the cells for western blotting.

Apoptosis detection. The cells were pretreated with sterile water or 10 mM NAC for 2 h and then treated with 0.1% DMSO or 40 µM wogonin for 24 h, prior to collection and washing three times in PBS. The cells were then resuspended in 100 µl 1X binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl and 2.5 mM CaCl₂), and 5 µl of Annexin V-fluorescein isothiocyanate (FITC) (Beyotime Institute of Biotechnology) and 5 µl of propidium iodide (PI; Beyotime Institute of Biotechnology) were added into the suspension, which was gently vortexed and incubated at room temperature for 15 min in the dark. The samples were assessed using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), and the data were analyzed by CellQuest Pro software (version 3.3; BD Biosciences) to determine the ratios of apoptotic cells.

Statistical analysis. Data are presented as the mean ± standard deviation from triplicated experiments. *P<0.01; **P<0.005. HPCC, human pancreatic cancer cell; CQ, chloroquine; LC3, microtubule-associated protein 1A/1B-light chain 3; GFP, green fluorescent protein; TEM, transmission electron microscopy; DMSO, dimethyl sulfoxide; siRNA, small interfering RNA; PI3K, phosphatidylinositol 3-kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Con, control; IgG, immunoglobulin G; IB, immunoblotting; IP, immunoprecipitation.
Results

Wogonin induces autophagy in HPCC. During autophagy, LC3-I is converted to LC3-II by lipidation through a ubiquitin-like system which involves Atg3 and Atg7; therefore, LC3 is associated with autophagic vesicles, and the presence of LC3 in autophagosomes and the presence LC3-II are the indicators of autophagy (16). In HPCCs, wogonin was observed to increase the expression levels of LC3-II; the quantified expression levels (wogonin/DMSO treatment) were 4.33 in Panc-1 cells and 1.58 in Colo-357 cells. In the rapamycin positive control group, the corresponding levels were 2.17 (Panc-1) and 3.49 (Colo-357). When wogonin was combined with CQ, an autophagy inhibitor that blocks the fusion of autophagosomes and lysosomes, an accumulation of LC3-II was observed [wogonin+CQ/DMSO levels: 4.61 (Panc-1) and 3.75 (Colo-357)] (Fig. 1A). These results indicate that wogonin promotes ROS generation in HPCCs, and the antioxidant NAC can attenuate the effect of wogonin on ROS generation. Data are presented as the mean ± standard deviation from triplicated experiments. *P<0.05; **P<0.005. HPCC, human pancreatic cancer cell; GSH, glutathione; DMSO, dimethyl sulfoxide; ROS, reactive oxygen species; NAC, N-acetyl-cysteine; DCFH-DA, 2,7-dichlorofluorescein diacetate; OD, optical density; DCF, 2,7-dichlorofluorescein.

Figure 3. Wogonin may promote ROS generation in HPCCs. HPCCs were pretreated with sterile water or NAC for 2 h and then treated with 0.1% DMSO or 40 µM wogonin for 24 h. (A) The levels of GSH were determined using an ELISA kit at 420 nm. Wogonin reduced the intracellular levels of GSH, and wogonin combined with NAC could significantly increase the intracellular levels of GSH. (B) The levels of O₂⁻ were determined using an ELISA kit at 550 nm. The intracellular levels of O₂⁻ were promoted by wogonin treatment and significantly inhibited by wogonin and NAC co-treatment. The levels of ROS were evaluated by DCFH-DA using (C) a fluorescence microscope or (D) a fluorescence microplate reader. ROS generation was promoted by wogonin treatment alone, but was inhibited by wogonin and NAC co-treatment. These results indicate that wogonin promotes ROS generation in HPCCs, and the antioxidant NAC can attenuate the effect of wogonin on ROS generation. Data are presented as the mean ± standard deviation from triplicated experiments. *P<0.05; **P<0.005. HPCC, human pancreatic cancer cell; GSH, glutathione; DMSO, dimethyl sulfoxide; ROS, reactive oxygen species; NAC, N-acetyl-cysteine; DCFH-DA, 2,7-dichlorofluorescein diacetate; OD, optical density; DCF, 2,7-dichlorofluorescein.
Let et al.: WOGONIN INDUCES AUTOPHAGY IN HUMAN PANCREATIC CANCER CELLS

5064

Wogonin induces autophagy through the ROS signaling pathway in HPCC. The results indicated that wogonin could increase the number of LC3-GFP puncta-positive cells, whereas co-treatment with NAC and wogonin attenuated this increase. Data were presented as the mean ± standard deviation from triplicated experiments. *P<0.05; **P<0.005. (A) AO staining for autolysosomes indicated that autolysosomes were activated by wogonin treatment, but inhibited by NAC and wogonin co-treatment. (C) Immunoblotting revealed that the expression levels of LC3 and ULK1 were downregulated by wogonin single treatment. (D) The levels of p-mTOR, t-mTOR, ULK1, AKT, 4E-BP1 and CYLD were evaluated by immunoblot. Wogonin could downregulate the expression of mTOR, and upregulate the expression levels of ULK1, AKT, 4E-BP1 and CYLD; these effects were significantly inhibited by NAC and wogonin co-treatment. AO, acridine orange; HPCC, human pancreatic cancer cell; DMSO, dimethyl sulfoxide; ROS, reactive oxygen species; NAC, N-acetyl-cysteine; LC3, microtubule-associated protein 1A/1B-light chain 3; GFP, green fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mTOR, mammalian target of rapamycin; P, phosphorylated; T, total; ULK1, Unc-51-like autophagy activating kinase; AKT, protein kinase B; 4E-BP1, 4E-binding protein-1; CYLD, cylindromatosis.

Figure 4. Wogonin induces autophagy through the ROS signaling pathway in HPCC. HPCC were pretreated with sterile water or NAC for 2 h, then treated with 0.1% DMSO or 40 µM wogonin for 24 h. (A) LC3-GFP puncta-positive cells were counted (≥5 puncta was considered positive) and the results indicated that wogonin could increase the number of LC3-GFP puncta-positive cells, whereas co-treatment with NAC and wogonin attenuated this increase. Data were presented as the mean ± standard deviation from triplicated experiments. *P<0.05; **P<0.005. (B) AO staining for autolysosomes indicated that autolysosomes were activated by wogonin treatment, but inhibited by NAC and wogonin co-treatment. (C) Immunoblotting revealed that the expression levels of LC3 were reduced by NAC and wogonin co-treatment compared with wogonin single treatment. (D) The levels of p-mTOR, t-mTOR, ULK1, AKT, 4E-BP1 and CYLD were evaluated by immunoblot. Wogonin could downregulate the expression of mTOR, and upregulate the expression levels of ULK1, AKT, 4E-BP1 and CYLD; these effects were significantly inhibited by NAC and wogonin co-treatment. AO, acridine orange; HPCC, human pancreatic cancer cell; DMSO, dimethyl sulfoxide; ROS, reactive oxygen species; NAC, N-acetyl-cysteine; LC3, microtubule-associated protein 1A/1B-light chain 3; GFP, green fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mTOR, mammalian target of rapamycin; P, phosphorylated; T, total; ULK1, Unc-51-like autophagy activating kinase; AKT, protein kinase B; 4E-BP1, 4E-binding protein-1; CYLD, cylindromatosis.

Wogonin may promote ROS generation in HPCC. ROS was observed to mediate the survival and proliferation of cancer cells; therefore, the current study investigated the variations in ROS levels induced by wogonin in HPCCs. The results demonstrated that wogonin decreases the levels of glutathione (GSH; Fig. 3A), increases the levels of superoxide (O₂⁻) and ROS (Fig. 3B-D). In addition, when the cells were co-treated with 10 mM of the antioxidant NAC, the effect of wogonin on GSH inhibition was reversed, and the level of GSH was significantly increased (Panc-1, P=0.003; Colo-357, P=0.001). Similarly, the effects of wogonin on O₂⁻ and ROS generation promotion were reversed; the levels of O₂⁻ (Panc-1, P=0.027; Colo-357, P=0.031) and ROS generation (Panc-1, P<0.001; Colo-357, P<0.001) were significantly decreased (Fig. 3A-D). Therefore, the results indicate that wogonin promotes ROS generation in HPCC, and the antioxidant NAC can attenuate the activation of ROS generation by wogonin.

Wogonin induces autophagy through the ROS signaling pathway in HPCC. As an antioxidant, NAC is considered as inhibitor of ROS. In order to negate the role of ROS in wogonin-induced autophagy, HPCCs were co-treated with 10 mM NAC and 40 µM wogonin. The results demonstrated that the quantity of LC3-GFP puncta in cells co-treated with NAC and wogonin was lower, as compared with the cells treated with wogonin alone (Panc-1, P=0.007; Colo-357, P=0.006; Fig. 4A). AO staining also indicated that when HPCCs were co-treated with NAC and wogonin, wogonin-induced autophagy was significantly reduced.
Autophagy was inhibited by NAC (Panc-1, \( P < 0.001 \); Colo-357, \( P < 0.001 \); Fig. 4B).

Similarly, LC3 expression was inhibited by NAC, as demonstrated when HPCCs were co-treated with NAC and wogonin (Fig. 4C). The results suggest that ROS may serve as an activator of wogonin-induced autophagy. The antioxidant NAC can inhibit the effect of ROS on autophagy activation. Further investigations are required to determine whether ROS are involved in additional pro-autophagy pathways in wogonin-induced autophagy.

Additional pro-autophagy pathways were detected to confirm whether they are involved in ROS-mediated autophagy following wogonin treatment. Previous reports (19-21) demonstrated that mTOR, ULK1, AKT, 4E-BP1 and CYLD participate in the mediation of autophagy. The present results revealed that wogonin could downregulate the expression of mTOR, and upregulate the expression of ULK1, AKT, 4E-BP1 and CYLD in HPCCs. When HPCCs were co-treated with wogonin and NAC, the effects of wogonin on the inhibition of mTOR, and the activation of ULK1, AKT, 4E-BP1 and CYLD were significantly attenuated. As the aforementioned results suggested that NAC could inhibit the generation of ROS in HPCCs, it is possible that mTOR, ULK1, AKT, 4E-BP1 and CYLD participate in wogonin-induced autophagy, acting as upstream signals of autophagy. In addition, these pro-autophagy molecules were mediated by ROS, acting as the downstream signals of ROS. Therefore, the pro-autophagy molecules mTOR, ULK1, AKT, 4E-BP1 and CYLD are involved in the ROS-mediated autophagy following wogonin treatment.

NAC may enhance wogonin-induced apoptotic cell death. To investigate the role of ROS-mediated autophagy in wogonin-induced-apoptotic cell death, HPCCs were treated with wogonin or co-treated with NAC and wogonin. The results demonstrated that co-treatment with NAC and wogonin was able to significantly enhance the wogonin-induced cell death ratio (Panc-1, \( P = 0.024 \); Colo-357, \( P = 0.037 \); Fig. 5A), and the ratio of cell viability was lower than in HPCCs treated with wogonin alone (Panc-1, \( P = 0.009 \); Colo-357, \( P = 0.008 \); Fig. 5B). Furthermore, when HPCCs were co-treated with NAC and wogonin, the apoptotic signaling molecule caspase-3 was activated (Fig. 5C). The results of Annexin V-FITC and PI staining...
revealed that NAC could enhance the ratio of apoptotic cells induced by wogonin (Panc-1, \(P=0.022\); Colo-357, \(P=0.039\)). Furthermore, when HPCCs were co-treated with NAC and wogonin, the apoptosis ratio of HPCCs was higher than with wogonin treatment alone (Panc-1, \(P=0.034\); Colo-357, \(P=0.026\); Fig. 5D). The results suggest that the suppression of ROS-mediated autophagy may enhance the antitumor potential of wogonin by increasing apoptosis in HPCCs.

**Discussion**

To the best of our knowledge, the present study is the first to demonstrate that wogonin-induced autophagy is regulated by the Beclin-1/Pi3K and ROS signaling pathways. Wogonin is able to activate Beclin-1 and Pi3K and promote ROS generation, inducing ROS-mediated autophagy, through activating ULK1, AKT, 4E-BP1 and CYLD, and inhibiting the mTOR signaling pathway (Fig. 6). The antitumor mechanisms underlying the role of wogonin in HPCC have been demonstrated to be an increase in apoptosis via the NF-κB, signal transducer and activator of transcription 3 and Pi3K/AKT signaling pathways, and induction of cell cycle arrest through modulation of the AKT/ glycogen synthase kinase 3/β-catenin signaling pathways (12,22-24). Additionally, wogonin has also exhibited anti-inflammatory effects; the mechanisms underlying the anti-inflammatory effects were demonstrated to be through the regulation of the NF-κB signaling pathway that is mediated by Toll-like receptor 4/myeloid differentiation primary response gene 88/transforming growth factor-β-activated kinase 1 (25-27). The effects of wogonin are not isolated: The anti-inflammatory function promotes apoptosis and cell cycle inhibition, although the underlying mechanisms of these three functions require further study.

Autophagy contributes to the survival of cells under various stresses, including starvation, drug stimulation and radiation, and is therefore a protective mechanism (16). The majority of chemotherapy drugs (including sorafenib, gemcitabine and paclitaxel) can induce autophagy in cancer cells, and autophagy acts a protective mechanism for cell. Drug-induced autophagy can make cells resistant to the therapeutic effect of the drug (28-30). Therefore, it is necessary to detect whether chemotherapy drugs can induce autophagy in cancer cells, and to investigate the mechanism of chemotherapy drug-induced autophagy in order to design more appropriate treatments for patients.

In mammalian cells, Pi3K can bind to Beclin-1 through special ECD and CCD domains to form the Beclin-1/Pi3K core complex, and then participate in the mediation of phosphorylation and ubiquitination, eventually inducing autophagy (31). In the present study it was shown that Beclin-1 interacts with Pi3K to form the Beclin-1/Pi3K complex, and that wogonin promoted the interaction of Beclin-1 and Pi3K, inducing autophagy in HPCCs. These results indicate that Beclin-1/Pi3K is important in wogonin-induced autophagy.

ROS can aggravate cell injury by oxidative stress. As the cell reacts to the injury, autophagy is activated to promote cell survival (32). With the promotion of the ROS-enhanced oxidative stress response, induced ROS can activate the transcription factors P53, NFE2-related factor 2 and hypoxia inducible factor 1, followed by the activation of LC3, P62 and NIP3-like protein X. Finally, the corresponding protein products can increase autophagic flux in the cytoplasm (32-35). In the present study, an increased level of ROS generation was observed in cells undergoing wogonin-induced autophagy, with upregulated \(O_2^-\) and downregulated GSH levels. Furthermore, the antioxidant NAC could block the activation of ROS generation and inhibit autophagic flux following wogonin treatment in HPCCs. These results indicate that ROS may serve as an activator in wogonin-induced autophagy in HPCCs. As previously reported, wogonin is an inhibitor of the mTOR pathway (16), and ULK1 may induce autophagy through regulation of the Beclin-1/VPS34 signaling pathway (19). Chow et al (14) reported that wogonin is able to induce autophagy and apoptosis by regulating the AKT signaling pathway. Lee et al (20) indicated that wogonin actives 4E-BP1, which is upstream of autophagy (21). The importance of CYLD in triggering autophagy has also been demonstrated (36). In the present study, wogonin was demonstrated to act as an inhibitor of mTOR and an activator of ULK1, AKT, 4E-BP1 and CYLD in HPCCs. In addition, the antioxidant NAC could attenuate the effect of wogonin on mTOR, ULK1, AKT, 4E-BP1 and CYLD, and inhibit wogonin-induced autophagy. These results indicate that the pro-autophagy molecules mTOR, ULK1, AKT, 4E-BP1 and CYLD are involved in the ROS-mediated autophagy following wogonin treatment in HPCCs. As ROS are involved in wogonin-induced autophagy, leading to inhibition of the cytotoxicity of wogonin for HPCCs, our results indicate that co-treatment with NAC and wogonin may be able to enhance wogonin-induced cell death through enhancement of apoptosis due to the ROS inhibition followed by autophagy inhibition. Thus, NAC may be a potential co-treatment with
wogonin in HPCCC, contributing to the antitumor effect of wogonin.

In summary, the findings of the present study indicate that wogonin can induce autophagy through activation of the Beclin-1/P13K complex and triggering the ROS-mediated autophagy pathway. The pro-autophagy molecules mTOR, ULK1, AKT, 4E-BP1 and CYLD are involved in the ROS-mediated autophagy following wogonin treatment. Furthermore, the antioxidant NAC can inhibit wogonin-induced autophagy through inhibition of ROS generation, and enhance the ratio of wogonin-induced apoptotic cell death. In the future, wogonin combined with NAC may be a novel combination therapy for clinical pancreatic cancer therapy trials.

References

1. Siegel R, Naishadham D and Jemal A: Cancer statistics 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Diener MK, Combs SE and Büchler MW: Chemoradiation therapy for locally advanced pancreatic cancer. Lancet Oncol 14: 269-270, 2013.
3. Akinmoto M, Iizuka M, Kanematsu R, Yoshida M and Takenaga K: Anticancer effect of ginger extract against pancreatic cancer cells mainly through reactive oxygen species-mediated autotic cell death. PLoS One 10: e0126605, 2015.
4. Lewis CS, Voelkel-Johnson C and Smith CD: Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the phoshingine kinase-2 inhibitor ABC294604. Oncotarget 2016. [Epub ahead of print]
5. Mandhare A, Biradar S and Gurule A: Azapeithalone B and its derivatives: A patent review. Expert Opin Ther Pat 26: 891-905, 2015.
6. Pourmorteza M, Rahman ZU and Young M: Etofosamide, a new horizon in the treatment of pancreatic cancer. Acta Oncologica 27: 723-725, 2016.
7. Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Köhler R, Gaisai M, Effert H, Desaubry L, Kramer PH and Li-Weber M: Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis 2: e182, 2011.
8. Polier G, Gaisai M, Köhler R, Müller WW, Lutz C, Büss EC, Kramer PH and Li-Weber M: Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer activity of the Bcl-2 family inhibitor ABT-263. Int J Cancer 136: 688-698, 2015.
9. Baumann S, Fas SC, Gaisai M, Müller WW, Merling A, Gikow K, Edler L, Kramer PH and Li-Weber M: Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1-and Ca2+ -dependent apoptosis. Blood 111: 2344-2363, 2008.
10. Yang Y, Liu X, Wang Q, Li H, Zhao K, Zhou Y, Zhu Y, Wang X, You Q, Guo Q and Lu N: Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget 5: 8188-8201, 2014.
11. Takahashi H, Chen MC, Pham H, Angst E, King JC, Park J, Browman EY, Ishiguro H, Harris DM, Reber HA, et al.: Baicalen, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta 1813: 1465-1474, 2011.
12. Kalliatidis G, Gaisai M, Müller WW, Merling A, Angst E, King JC, Park J, Browman EY, Ishiguro H, Harris DM, Reber HA, et al.: Baicalen, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta 1813: 1465-1474, 2011.
13. Chow SE, Chen YW, Liang CA, Huang YK and Wang JS: Wogonin induces cross-regulation between autophagy and apoptosis via a variety of Akt pathway in human nasopharyngeal carcinoma cells. J Cell Biochem 113: 3476-3485, 2012.
14. Zhu Y and Wang J: Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: Potential drug to treat Alzheimer’s disease. Neurourol Urodyn 34: 1881-1889, 2015.
15. Klöppel DI, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al.: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12: 1-226, 2016.
16. Steinbrenner J, Eldridge M, Tomé DF and Beynon JL: A simple and fast protocol for the protein complex immuno-precipitation (Co-IP) of effector: Host protein complexes. Methods Mol Biol 1127: 195-211, 2014.
17. Oztylova O, Stratton Y, Hall D, Kellner E, Ebhier B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J and Czyzyk-Krzeska MF: VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell 21: 532-546, 2012.
18. Hoshida RC, Tian Y, Yuan H, Park HW, Chang YY, Kim Y, Kim H, Neufeld TP, Dillin A and Guan KL: ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol 15: 741-750, 2013.
19. Lee DH, Lee TH, Jung CH and Kim YH: Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells. Cell Signal 24: 2216-2235, 2012.
20. Thomas HE, Mercer CA, Carnevali LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwamani A, Aronow BJ, et al.: mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 4: 139ra84, 2012.
21. Xiao W, Wu K, Yin M, Han S, Ding Y, Qiao A, Lu G, Deng B, Bo P and Gong W: Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity. J Immunother 38: 167-184, 2015.
22. Liu X, Mu M, Qin R, Wang Y and Wu D: Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway. Oncol Rep 33: 3146-3154, 2015.
23. Zhao L, Miao HC, Li WJ, Sun Y, Huang SL, Li ZY and Guo J: LW-213 induces G2/M cell cycle arrest through AKT/GSK3β-catening signaling pathway in human breast cancer cells. Mol Carcinog 55: 778-792, 2015.
24. Wang W, Xia T and Yu X: Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-κB pathway in vitro. Int J Mol Sci 16: 423-431, 2015.
25. Satoh T, Fujii Y, Nagao T and Ichihara T: Anti-inflammatory effect of wogonin on RAW 264.7 mouse macrophages induced by polysaccharin-polymericidylic acid. Molecules 20: 6888-6900, 2015.
26. Lucas CD, Dorward DA, Sharma S, Rennie J, Felton JM, Alessandri AL, Duffin R, Schwarz J, Haslett C and Rossi AG: Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation. Am J Respir Crit Care Med 191: 626-635, 2015.
27. Prieto-Dominguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J and Mauriz JL: Modulation of autophagy by soraflin: Effects on Treatment Response. Front Pharmacol 7: 151, 2016.
28. Kugler A, Perkofofer L and Seufferlein T: Smarter drugs emerging on the horizon in the treatment of pancreatic cancer. Anticancer Drugs 27: 423-431, 2016.
29. Wang L, Xia T and Yu X: Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-kB pathway in vitro. Int J Mol Sci 16: 423-431, 2015.
30. Prieto-Dominguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J and Mauriz JL: Modulation of autophagy by soraflin: Effects on Treatment Response. Front Pharmacol 7: 151, 2016.
31. Scherz-Shouval R and Elazar Z: Regulation of autophagy by sorafenib: Effects on Treatment Response. Front Pharmacol 7: 151, 2016.
32. Kugler A, Perkofofer L and Seufferlein T: Smarter drugs emerging on the horizon in the treatment of pancreatic cancer. Anticancer Drugs 27: 423-431, 2016.
33. Prieto-Dominguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J and Mauriz JL: Modulation of autophagy by soraflin: Effects on Treatment Response. Front Pharmacol 7: 151, 2016.
34. Kugler A, Perkofofer L and Seufferlein T: Smarter drugs emerging on the horizon in the treatment of pancreatic cancer. Anticancer Drugs 27: 423-431, 2016.
35. Prieto-Dominguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J and Mauriz JL: Modulation of autophagy by soraflin: Effects on Treatment Response. Front Pharmacol 7: 151, 2016.
36. Kugler A, Perkofofer L and Seufferlein T: Smarter drugs emerging on the horizon in the treatment of pancreatic cancer. Anticancer Drugs 27: 423-431, 2016.